Contributions
Abstract: EP1455
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 12 Pathology
Background: Recent evidence suggests that the intestine might be an early site of MS disease in response to environmental toxins. Disruption of the intestinal barrier integrity is one potential mechanism for which the noxious luminal products (including bacterial lipopolysaccharide, LPS) induces mucosal immune dysfunction and systemic immune activation, which might trigger the development of MS. The interaction of LPS with factors such as LPS binding protein (LBP) and soluble CD14 (sCD14) are key events on LPS-induces activation of the innate immune system. Thus, LBP and sCD14 are considered as indirect markers of bacterial translocation.
Aims: To explore the utility of intestinal permeability markers (intestinal fatty acid binding protein, I-FABP) and microbial translocation (LBP and sCD14) in early MS.
Methods: Tirthy six patients were included (19 early MS, 3 RIS, and 14 patients afected by other CNS diseases different from MS). Blood samples were collected with a mean delay from the MS onset to the blood test: 5,6 month, and all were free of immunomodulatory treatment. Clinical and MRI data were collected and correlated with the biological molecules. Serum levels of LBP, sCD14 and I-FABP were measured by commercial ELISA kit.
Results: Serum levels of LBP, sCD14 and I-FABP did not differ between the 3 clinical phenotypes. Considering the MS group, levels of LBP positively correlated with the relapse rate throughout the follow up (r 0.54, p=0.02). Findings are in accordance with both the LBP role in activating innate immune responses, and the involvement of the innate inmune system in the acute inflammatory events in MS.
Conclusions: LBP could have utility in the clinical activity to improve the prediction of relapse risk in early MS patients. Further research should be performed in a larger cohort of patients in order to confirm these results.
Disclosure:
Nieves Tellez has nothing to disclose,
Patricia Mulero has nothing to disclose,
Natan Redondo has nothing to disclose,
MJose Neri has nothing to disclose,
MªLuisa Nieto has nothing to disclose,
Marita Hernandez has nothing to disclose,
Beatriz Gutierrez has nothing to disclose,
Isabel Gallardo has nothing to disclose
Abstract: EP1455
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 12 Pathology
Background: Recent evidence suggests that the intestine might be an early site of MS disease in response to environmental toxins. Disruption of the intestinal barrier integrity is one potential mechanism for which the noxious luminal products (including bacterial lipopolysaccharide, LPS) induces mucosal immune dysfunction and systemic immune activation, which might trigger the development of MS. The interaction of LPS with factors such as LPS binding protein (LBP) and soluble CD14 (sCD14) are key events on LPS-induces activation of the innate immune system. Thus, LBP and sCD14 are considered as indirect markers of bacterial translocation.
Aims: To explore the utility of intestinal permeability markers (intestinal fatty acid binding protein, I-FABP) and microbial translocation (LBP and sCD14) in early MS.
Methods: Tirthy six patients were included (19 early MS, 3 RIS, and 14 patients afected by other CNS diseases different from MS). Blood samples were collected with a mean delay from the MS onset to the blood test: 5,6 month, and all were free of immunomodulatory treatment. Clinical and MRI data were collected and correlated with the biological molecules. Serum levels of LBP, sCD14 and I-FABP were measured by commercial ELISA kit.
Results: Serum levels of LBP, sCD14 and I-FABP did not differ between the 3 clinical phenotypes. Considering the MS group, levels of LBP positively correlated with the relapse rate throughout the follow up (r 0.54, p=0.02). Findings are in accordance with both the LBP role in activating innate immune responses, and the involvement of the innate inmune system in the acute inflammatory events in MS.
Conclusions: LBP could have utility in the clinical activity to improve the prediction of relapse risk in early MS patients. Further research should be performed in a larger cohort of patients in order to confirm these results.
Disclosure:
Nieves Tellez has nothing to disclose,
Patricia Mulero has nothing to disclose,
Natan Redondo has nothing to disclose,
MJose Neri has nothing to disclose,
MªLuisa Nieto has nothing to disclose,
Marita Hernandez has nothing to disclose,
Beatriz Gutierrez has nothing to disclose,
Isabel Gallardo has nothing to disclose